Live feed06:00:00·7mPRReleasevia QuantisnowIDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung CancerByQuantisnow·Wall Street's wire, on your screen.IDYA· IDEAYA Biosciences Inc.Health Care
